Fruquintinib significantly extends survival in refractory metastatic colorectal cancer

Treatment with fruquintinib resulted in a significant and clinically meaningful survival benefit when compared with placebo among patients with refractory metastatic colorectal cancer, according to data published in The Lancet.Results of the randomized phase 3 FRESCO-2 study showed treatment with the VEGFR inhibitor extended median OS by about 2.6 months among this patient population, which has few treatment options and typically poor outcomes.“It was extremely important to find another option for previously treated patients with metastatic colorectal cancer that would provideRead More